Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to “Outperform” at Leerink Partners

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by Leerink Partners from a “market perform” rating to an “outperform” rating in a research report issued on Wednesday, Marketbeat.com reports. The brokerage currently has a $834.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $762.00. Leerink Partners’ price target would indicate a potential upside of 15.50% from the company’s previous close.

Several other research firms have also issued reports on REGN. Evercore ISI lowered their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $722.07 on Wednesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company’s fifty day simple moving average is $717.27 and its 200-day simple moving average is $914.93. Regeneron Pharmaceuticals has a 12 month low of $642.00 and a 12 month high of $1,211.20. The firm has a market cap of $79.35 billion, a PE ratio of 17.87, a P/E/G ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the company earned $11.86 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals will post 37.75 EPS for the current fiscal year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. UMB Bank n.a. increased its stake in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the last quarter. Adirondack Trust Co. lifted its holdings in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares during the last quarter. Trust Co. of Vermont lifted its holdings in Regeneron Pharmaceuticals by 8.3% during the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 12 shares during the last quarter. Nvwm LLC lifted its holdings in Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 14 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 3.6% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.